...execution, culminating in the launch of Velcade bortezomib...

...of oncology he led global cancer strategy and execution, culminating in the launch of Velcade bortezomib...

...detailed data from the Phase III BOSTON trial that showed Xpovio selinexor plus once-weekly Velcade bortezomib...

...In about 402 second- to fourth-line MM patients in BOSTON, once-weekly Xpovio plus Velcade bortezomib...
...J.P. Morgan, Morgan Stanley and Jefferies. Targets XPO1 (CRM1) - Exportin 1 Sandi Wong, Assistant Editor Velcade, bortezomib...

...In both a xenograft mouse model of MM resistant to the marketed MM drug Velcade bortezomib...

...an anti-CD-38 mAb from the Janssen-Cilag International NV unit of Johnson & Johnson (NYSE:JNJ), with bortezomib...

...Bertozzi’s work suggests NGLY1 inhibitors can boost the antitumor efficacy of proteasome inhibitors carfilzomib and bortezomib...

...Phase II Genmab A/S (CSE:GEN; Pink:GMXAY) said Darzalex daratumumab in combination with Revlimid lenalidomide, Velcade bortezomib...

...subgroup data from the Phase IIb STORM study. The event-driven BOSTON is evaluating Xpovio, Velcade bortezomib...

...received Priority Review from FDA for an sBLA for Darzalex daratumumab in combination with Velcade bortezomib...
...ineligible for ASCT. Jonathan Block, Associate Editor Abraxane, nab-paclitaxel (ABI-007) Camrelizumab (INCSHR1210, SHR-1210) Darzalex, daratumumab (JNJ-54767414, humax-cd38) sintilimab (IBI308) tislelizumab (BGB-A317) Velcade, bortezomib...